Abstract
The balance between T helper (h)1 and Th2 responsiveness seems to represent a key event in the evolution of hepatitis C virus (HCV) infection. In particular, Th1 cytokines [interleukin (IL-2) and interferon (IFN-γ)] have been demonstrated to mediate the antiviral immune response. Serum levels of Th1 cytokines (IL-2 and IFN-γ) as well as of Th2 products (IL-4 and IL-10) were determined in a group of HCV-positive patients before and after treatment with IFN-α and Ribavirin (RIB). Results indicate that responder patients exhibited increased levels of IFN-γ and IL-10, while this enhancement was not observed in non-responder patients. In this respect, the major effect exerted by the combined therapy with IFN-α / RIB could be represented by the attainment of a re-equilibrium between inflammatory (Th1) and antiinflammatory (Th2) mechanisms. In this framework, according to current literature, novel therapeutical approaches to treat HCV infection are represented by administration of recombinant IL-2 and IL-10.
Keywords: ifn, ribavirin, responsiveness, gamma, interleukin, recombinant interleukin
Current Pharmaceutical Design
Title: Modifications of the Immune Responsiveness in Patients with Hepatitis C Virus Infection following Treatment with IFN-α / Ribavirin
Volume: 8 Issue: 11
Author(s): L. Amati, L. Caradonna, T. Magrone, M. L. Mastronardi, R. Cuppone, R. Cozzolongo, O. G. Manghisi, D. Caccavo, A. Amoroso and E. Jirillo
Affiliation:
Keywords: ifn, ribavirin, responsiveness, gamma, interleukin, recombinant interleukin
Abstract: The balance between T helper (h)1 and Th2 responsiveness seems to represent a key event in the evolution of hepatitis C virus (HCV) infection. In particular, Th1 cytokines [interleukin (IL-2) and interferon (IFN-γ)] have been demonstrated to mediate the antiviral immune response. Serum levels of Th1 cytokines (IL-2 and IFN-γ) as well as of Th2 products (IL-4 and IL-10) were determined in a group of HCV-positive patients before and after treatment with IFN-α and Ribavirin (RIB). Results indicate that responder patients exhibited increased levels of IFN-γ and IL-10, while this enhancement was not observed in non-responder patients. In this respect, the major effect exerted by the combined therapy with IFN-α / RIB could be represented by the attainment of a re-equilibrium between inflammatory (Th1) and antiinflammatory (Th2) mechanisms. In this framework, according to current literature, novel therapeutical approaches to treat HCV infection are represented by administration of recombinant IL-2 and IL-10.
Export Options
About this article
Cite this article as:
Amati L., Caradonna L., Magrone T., Mastronardi L. M., Cuppone R., Cozzolongo R., Manghisi G. O., Caccavo D., Amoroso A. and Jirillo E., Modifications of the Immune Responsiveness in Patients with Hepatitis C Virus Infection following Treatment with IFN-α / Ribavirin, Current Pharmaceutical Design 2002; 8 (11) . https://dx.doi.org/10.2174/1381612024607036
DOI https://dx.doi.org/10.2174/1381612024607036 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Safety and Efficacy of Eltrombopag in Children and Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis
Cardiovascular & Hematological Agents in Medicinal Chemistry Metabolomics of Serum Peptides
Protein & Peptide Letters Lentiviral Vectors for Anti-Tumor Immunotherapy
Current Gene Therapy Analysis of Trends and Opportunities of Anti-Allergy Patents in China from 1998 to 2008
Recent Patents on Inflammation & Allergy Drug Discovery The Role of Bacterial DNA in Inflammatory and Allergic Disease
Recent Patents on Inflammation & Allergy Drug Discovery Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Infectious Agents and Neurodegenerative Diseases: Exploring the Links
Current Topics in Medicinal Chemistry HCV-Related Rheumatic Manifestations and Therapeutic Strategies
Current Drug Targets Administration of Autologous Mesenchymal Cells for the Treatment of Arthritis
Current Stem Cell Research & Therapy Oseltamivir Pharmacology in Young Children: A Commentary
Infectious Disorders - Drug Targets Clinical Uses of Low – Dose Ketamine in Patients Undergoing Surgery
Current Drug Targets Therapy of Chronic Hepatitis C in the Era of Nanotechnology: Drug Delivery Systems and Liver Targeting
Mini-Reviews in Medicinal Chemistry Update on Sensitivity to Nonsteroidal Antiinflammatory Drugs
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Cytokines and Chemokines as Regulators of Angiogenesis in Health and Disease
Current Pharmaceutical Design The Role of Antihistamines in the Management of Allergic Rhinitis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Reactive Oxygen Species in Myocardial Reperfusion Injury: From Physiopathology to Therapeutic Approaches
Current Pharmaceutical Biotechnology Molecular Mechanisms of the Antiatherogenic Action of Adiponectin
Vascular Disease Prevention (Discontinued) Recent Approaches for Studying the Role of Glia
CNS & Neurological Disorders - Drug Targets Quilizumab is an Afucosylated Humanized Anti-M1 Prime Therapeutic Antibody
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) First-Line Treatment of Multiple Myeloma in Elderly Patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dellAdulto) Multiple Myeloma Working Party Perspective
Current Drug Targets